

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release of Security Interest

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Alpharma Pharmaceuticals LLC		05/11/2010	LIMITED LIABILITY COMPANY: UNITED STATES

RECEIVING PARTY DATA

Name:	CREDIT SUISSE AG
Street Address:	11 Madison Avenue
Internal Address:	As Administrative Agent
City:	New York
State/Country:	NEW YORK
Postal Code:	10010
Entity Type:	Bank: SWITZERLAND

PROPERTY NUMBERS Total: 13

Property Type	Number	Word Mark
Registration Number:	3473264	MAXIMIZE RELIEF. MINIMIZE ABUSE.
Registration Number:	3473263	PAINBALANCE
Serial Number:	77196833	ANCLOSIV
Serial Number:	77462327	DEACTICORE
Serial Number:	77331799	EMBEDA
Serial Number:	77196837	EMSENAL
Serial Number:	77205308	EMSENT
Serial Number:	77007329	FIGHTING MAD
Serial Number:	77390077	FLEX
Serial Number:	77311187	MAXIMIZE RELIEF. MINIMIZE EXPOSURE.
Serial Number:	77336776	OXSENAL
Serial Number:	77333124	PAINPOINT
Serial Number:	77333091	PAINPOINTS

TRADEMARK

CORRESPONDENCE DATA

Fax Number: (800)494-7512
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: (202) 370-4761
Email: ecallahan@nationalcorp.com
Correspondent Name: Elspeth Callahan
Address Line 1: 1100 G St NW Suite 420
Address Line 2: National Corporate Research
Address Line 4: Washington, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER:	F 126672
NAME OF SUBMITTER:	Mariee Pilkington
Signature:	/Mariee Pilkington/
Date:	05/11/2010
Total Attachments: 3 source=T.Release - Alharma Pharmaceuticals#page2.tif source=T.Release - Alharma Pharmaceuticals#page3.tif source=T.Release - Alharma Pharmaceuticals#page4.tif	

Release of Security Interest in Trademarks

May 11, 2010

WHEREAS, King Pharmaceuticals, Inc., certain of its subsidiaries and Credit Suisse AG, Cayman Islands Branch (formerly Credit Suisse, Cayman Islands Branch) (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated December 29, 2008;

WHEREAS, pursuant to the GCA, Credit Suisse and Alpharma Pharmaceuticals LLC (the “**Assignee**”) entered into that certain Trademark Security Agreement dated December 29, 2008 and recorded with the United States Patent and Trademark Office on December 30, 2008 on Reel No. 3911, Frame 0752 (the “**Trademark Security Agreement**”);

WHEREAS, under the Trademark Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Trademark Collateral (as defined in the Trademark Security Agreement), including those items set forth on Schedule 1 hereto (the “**Released Trademark Collateral**”); and


WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Trademark Security Agreement in the Released Trademark Collateral.


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Trademark Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Trademark Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors and upon the Secured Parties. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.

[signature page to follow]

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officer thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN
ISLANDS BRANCH

By: 
Name: DOREEN BARR
Title: DIRECTOR

By: 
Name: VIPUL DHADDA
Title: ASSOCIATE

[signature page – Alharma Pharmaceuticals LLC trademark release]

Schedule 1

Alpharma Pharmaceuticals LLC

TRADEMARKS

Trademark	Registration No.	Registration Date
MAXIMIZE RELIEF, MINIMIZE ABUSE	3,473,264	July 22, 2008
PAINBALANCE	3,473,263	July 22, 2008

TRADEMARK APPLICATIONS

Trademark	Application No.	Application Date
ANCLOSIV	77196833	Jun 4, 2007
DEACTICORE	77462327	April 30, 2008
EMBEDA	77331799	Nov 16, 2007
EMSENAL	77196837	June 4, 2007
EMSENT	77205308	June 13, 2007
FIGHTING MAD	77007329	Sept 26, 2006
FLEX	77390077	Feb 6, 2008
MAXIMUM RELIEF, MINIMIZE EXPOSURE	77311187	Oct 23, 2007
OXSENAL	77336776	Nov 26, 2007
PAINPOINT	77333124	Nov 19, 2007
PAINPOINTS	77333091	Nov 19, 2007

TRADEMARK LICENSES

Name of Agreement	Parties Licensor/Licensee	Date of Agreement	Subject Matter
Exclusive license and Distribution Agreement	IBSA (Institut Biochimique SA) / Alpharma Pharmaceuticals LLC	August 16, 2007	Flector Patch
Exclusive License and Distribution Agreement	IBSA (Institut Biochimique SA) / Alpharma Pharmaceuticals LLC	August 16, 2007	Tirosint